The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
The cost of diabetes care-an elephant in the room
Abstract
Everyone dealing with health care today knows there is an elephant in the room, impossible to miss but frequently ignored—the cost of diabetes care. Although clinicians and scientists may wish to neglect the financial side of diabetes care and focus on less contentious and more familiar matters, this option is no longer viable. For people with diabetes and their families, the elephant stands in the way every day, and for those who plan health services and payment, it is a major concern. Fortunately, the scientific methods used in epidemiologic, clinical, and health services research can be applied to the economics of diabetes care. Collecting observations, identifying patterns, forming hypotheses, and prospectively testing the hypotheses can be just as relevant when one of the variables examined is the cost of care. It is the mission of Diabetes Care to present the best scientific studies related to diabetes. This issue of Diabetes Care has a special section focused on the economic impact of diabetes, including studies designed to understand it and to assess potential solutions. The American Diabetes Association (ADA) has previously reported the costs of diabetes in the U.S. for the years 2002 (1), 2007 (2), and 2012 (3). This issue of Diabetes Care includes a 2017 update (4). Because the methods used in these analyses are similar, comparisons are possible. The most noteworthy findings from the current report are the continuing increase and the remarkable magnitude of the tot…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Costs for noninsulin and insulin diabetes medications have increased dramatically over the past two decades, and an increasing proportion of cost is now passed on to people with diabetes and their families (194).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [194]
In the citing paper
“Costs for noninsulin and insulin diabetes medications have increased dramatically over the past two decades, and an increasing proportion of cost is now passed on to people with diabetes and their families (194).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [194]
Citations
Cites
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold
Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1405158 · Cited by 2,249
Economic Costs of Diabetes in the U.S. in 2012
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc12-2625 · Cited by 2,227
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030
Bommer, C., Sagalova, V., Heesemann, E., Manne‐Goehler, J., Atun, R. A., Bärnighausen, T., Davies, J. I., & Vollmer, S. (2018) · Diabetes Care · doi:10.2337/dc17-1962 · Cited by 1,137
Economic Costs of Diabetes in the U.S. in 2007
Leahy, J. L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79219-9 · Cited by 781
Economic Costs of Diabetes in the U.S. in 2002Preprint
Dall, T. M., Nikolov, P., & Hogan, P. F. (2003) · RePEc: Research Papers in Economics · Cited by 482
The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1468 · Cited by 436
Ely, E. K., Gruss, S. M., Luman, E. T., Gregg, E. W., Ali, M. K., Nhim, K., Rolka, D. B., & Albright, A. L. (2017) · Diabetes Care · doi:10.2337/dc16-2099 · Cited by 386
Health Care Costs Associated With Incident Complications in Patients With Type 2 Diabetes in Germany
Kähm, K., Laxy, M., Schneider, U., Rogowski, W. H., Lhachimi, S. K., & Holle, R. (2018) · Diabetes Care · doi:10.2337/dc17-1763 · Cited by 141
Wan, E. Y. F., Fung, C. S. C., Jiao, F. F., Yu, E. Y. T., Chin, W. Y., Fong, D., Wong, C. K. H., Chan, A. K. C., Chan, K. H. Y., Kwok, R. L. P., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0426 · Cited by 132
Berkowitz, S. A., Kalkhoran, S. M., Edwards, S. T., Essien, U. R., & Baggett, T. P. (2018) · Diabetes Care · doi:10.2337/dc17-1812 · Cited by 93
Moin, T., Li, J., Duru, O. K., Ettner, S., Turk, N., Keckhafer, A., Ho, S., & Mangione, C. M. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1773 · Cited by 90
The Productivity Burden of Diabetes at a Population Level
Magliano, D. J., Martin, V. J., Owen, A. J., Zomer, E., & Liew, D. (2018) · Diabetes Care · doi:10.2337/dc17-2138 · Cited by 83
Herman, W. H., Pan, Q., Edelstein, S. L., Mather, K. J., Perreault, L., Barrett-Connor, E. L., Dabelea, D., Horton, E. S., Kahn, S. E., Knowler, W. C., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1116 · Cited by 78
Self-citationJiao, F. F., Fung, C. S. C., Wan, E. Y. F., Chan, A. K. C., McGhee, S. M., Kwok, R. L. P., & Lam, C. L. K. (2017) · Diabetes Care · doi:10.2337/dc17-1149 · Cited by 68
Wharam, J. F., Zhang, F., Eggleston, E., Lu, C. Y., Soumerai, S. B., & Ross‐Degnan, D. (2018) · Diabetes Care · doi:10.2337/dc17-1183 · Cited by 54
Casagrande, S. S., McEwen, L. N., & Herman, W. H. (2018) · Diabetes Care · doi:10.2337/dc17-2524 · Cited by 52
Self-citationDeclines in the Incidence of Diabetes in the U.S.—Real Progress or Artifact?
Selvin, E., & Ali, M. K. (2017) · Diabetes Care · doi:10.2337/dc16-2442 · Cited by 49
The National Diabetes Education Program at 20 Years: Lessons Learned and Plans for the Future
Siminerio, L. M., Albright, A. L., FRADKIN, J. E., Gallivan, J. M., McDivitt, J., Rodríguez, B., Tuncer, D. M., & Wong, F. L. (2018) · Diabetes Care · doi:10.2337/dc17-0976 · Cited by 42
Nuckols, T. K., Keeler, E. B., Anderson, L., Green, J., Morton, S. C., Doyle, B. J., Shetty, K. D., Arifkhanova, A., Booth, M. S., Shanman, R., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1495 · Cited by 40
Gregg, E. W. (2017) · Diabetes Care · doi:10.2337/dci16-0055 · Cited by 26
Puckrein, G. A., Nunlee‐Bland, G., Zangeneh, F., Davidson, J. A., Vigersky, R. A., Xu, L., Parkin, C. G., & Marrero, D. G. (2016) · Diabetes Care · doi:10.2337/dc15-1264 · Cited by 22
Trends in Diabetes-Related Preventable Hospitalizations in the U.S., 2005–2014
Rubens, M., Saxena, A., Ramamoorthy, V., Khera, R., Hong, J. C., Veledar, E., & Nasir, K. (2018) · Diabetes Care · doi:10.2337/dc17-1942 · Cited by 22
Impact of the 2013 National Rollout of CMS Competitive Bidding Program: The Disruption Continues
Puckrein, G. A., Hirsch, I. B., Parkin, C. G., Taylor, B. T., Xu, L., & Marrero, D. G. (2017) · Diabetes Care · doi:10.2337/dc17-0960 · Cited by 5
Flagged first, then by citations
Cited by
Sorted by citations
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Metadata
- Authors
- Riddle, M. C., & Herman, W. H.
- Affiliations
- Oregon Health & Science University (US)
- University of Michigan (US)
- Corresponding author
- Riddle, Matthew C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-04-12
- Volume
- 41
- Issue
- 5
- Pages
- 929-932
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2801768830
- Cited by
- 191
- References
- 26
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 23 · 2023: 32 · 2022: 31 · 2021: 37 · 2020: 39 · 2019: 14 · 2018: 2
- FWCI
- 35.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetes care costs, economic burden of diabetes, health care expenditure, health care payment, health planning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
